Low-risk patients with myelodysplastic syndromes (MDS) are inclined to long-term accumulation of iron in the organs due mostly to red blood cell transfusion and ineffective erythropoiesis. The effect of free toxic iron species in the liver and heart sites is well known, but recent knowledge assumes that oxidant-mediated tissue injury is also effective in the bone marrow. We aimed to investigate the predictive value of bone marrow iron accumulation as demonstrated by Perls staining on the overall survival (OS) of MDS patients. We retrospectively analyzed 114 low and intermediate-I IPSS risk MDS patients who were diagnosed at our institution in the last 20 years. The median age was 70 years (range 32–93). Two different experienced hematologists analyzed all samples. Perls Prussian blue stain was used to stain the bone marrow, which was assessed by modified Gale’s grading and then correlated with the outcome. Twenty-seven patients had grade 1 (+), 31 grade 2 (++), and 56 grade 3 (+++). The 20-year OS was significantly lower in patients with a higher Perls score (6.8 ± 6.1%, median 80 ± 7 months in grade 3; 18.7 ± 9.4%, median 70 ± 17 months in grade 2; 33.2 ± 16.4%, median 144 ± 18 months in grade 1; p = 0.011); bone marrow iron overload (p = 0.003; HR 1.7) and transfusion dependency (0.001; HR 2.6) negatively impacted on survival. We suggest that a higher grade of iron storage at diagnosis can impact on the outcome in MDS patients. Perls stain, together with ferritin and the blood transfusional burden, could be another marker at diagnosis of iron-related toxicity that predicts survival.

1.
Pilo
F
,
Di Tucci
AA
,
Dessalvi
P
,
Caddori
A
,
Angelucci
E
.
The evolving clinical scenario of myelodysplastic syndrome: the need for a complete and up to date upfront diagnostic assessment
.
Eur J Intern Med
.
2010
Dec
;
21
(
6
):
490
5
.
[PubMed]
0953-6205
2.
Santini
V
.
Anemia as the Main Manifestation of Myelodysplastic Syndromes
.
Semin Hematol
.
2015
Oct
;
52
(
4
):
348
56
.
[PubMed]
0037-1963
3.
Greenberg
PL
,
Tuechler
H
,
Schanz
J
,
Sanz
G
,
Garcia-Manero
G
,
Solé
F
, et al
Revised international prognostic scoring system for myelodysplastic syndromes
.
Blood
.
2012
Sep
;
120
(
12
):
2454
65
.
[PubMed]
0006-4971
4.
Pilo
F
,
Angelucci
E
.
A storm in the niche: Iron, oxidative stress and haemopoiesis
.
Blood Rev
.
2018
Jan
;
32
(
1
):
29
35
.
[PubMed]
0268-960X
5.
Kautz
L
,
Jung
G
,
Valore
EV
,
Rivella
S
,
Nemeth
E
,
Ganz
T
.
Identification of erythroferrone as an erythroid regulator of iron metabolism
.
Nat Genet
.
2014
Jul
;
46
(
7
):
678
84
.
[PubMed]
1061-4036
6.
Nemeth
E
,
Tuttle
MS
,
Powelson
J
,
Vaughn
MB
,
Donovan
A
,
Ward
DM
, et al
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization
.
Science
.
2004
Dec
;
306
(
5704
):
2090
3
.
[PubMed]
0036-8075
7.
Malcovati
L
.
Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes
.
Leuk Res
.
2007
Dec
;
31
Suppl 3
:
S2
6
.
[PubMed]
0145-2126
8.
Efficace
F
,
Gaidano
G
,
Sprangers
M
,
Cottone
F
,
Breccia
M
,
Voso
MT
, et al
Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes
.
Ann Oncol
.
2014
Feb
;
25
(
2
):
447
54
.
[PubMed]
0923-7534
9.
Caocci
G
,
La Nasa
G
,
Efficace
F
.
Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes
.
Expert Rev Hematol
.
2009
Feb
;
2
(
1
):
69
80
.
[PubMed]
1747-4086
10.
Goldberg
SL
,
Chen
E
,
Corral
M
,
Guo
A
,
Mody-Patel
N
,
Pecora
AL
, et al
Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries
.
J Clin Oncol
.
2010
Jun
;
28
(
17
):
2847
52
.
[PubMed]
0732-183X
11.
Chai
X
,
Li
D
,
Cao
X
,
Zhang
Y
,
Mu
J
,
Lu
W
, et al
ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice
.
Sci Rep
.
2015
May
;
5
(
1
):
10181
.
[PubMed]
2045-2322
12.
Stuart-Smith
SE
,
Hughes
DA
,
Bain
BJ
.
Are routine iron stains on bone marrow trephine biopsy specimens necessary?
J Clin Pathol
.
2005
Mar
;
58
(
3
):
269
72
.
[PubMed]
0021-9746
13.
Bableshwar
RS
,
Roy
M
,
Bali
A
,
Patil
PV
,
Inumella
S
.
Intensive method of assessment and classification of the bone marrow iron status: a study of 80 patients
.
Indian J Pathol Microbiol
.
2013
Jan-Mar
;
56
(
1
):
16
9
.
[PubMed]
0377-4929
14.
Malcovati
L
,
Porta
MG
,
Pascutto
C
,
Invernizzi
R
,
Boni
M
,
Travaglino
E
, et al
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
.
J Clin Oncol
.
2005
Oct
;
23
(
30
):
7594
603
.
[PubMed]
0732-183X
15.
Arber
DA
,
Orazi
A
,
Hasserjian
R
,
Thiele
J
,
Borowitz
MJ
,
Le Beau
MM
, et al
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Blood.
2016
19;127(20):2391–405.
16.
Pujara
KM
,
Bhalara
RV
,
Dhruva
GA
.
A study of bone marrow iron storage in hematological disorder
.
Int J Health Allied Sci
.
2014
Jan
;
3
(
4
):
221
. 2278-344X
17.
Gale
E
,
Torrance
J
,
Bothwell
T
.
The quantitative estimation of total iron stores in human bone marrow
.
J Clin Invest
.
1963
Jul
;
42
(
7
):
1076
82
.
[PubMed]
0021-9738
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.